247 related articles for article (PubMed ID: 36647502)
1. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
2. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
Tjong MC; Louie AV; Iyengar P; Solomon BJ; Palma DA; Siva S
Transl Lung Cancer Res; 2021 Jul; 10(7):3446-3456. PubMed ID: 34430379
[TBL] [Abstract][Full Text] [Related]
3. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
4. Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Santos PMG; Li X; Gomez DR
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010969
[TBL] [Abstract][Full Text] [Related]
5. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer.
Chicas-Sett R; Castilla Martinez J; Hernández Blanquisett A; Zafra J; Pastor-Peidro J
Front Oncol; 2022; 12():1092875. PubMed ID: 36727053
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gan GN; Weickhardt AJ; Scheier B; Doebele RC; Gaspar LE; Kavanagh BD; Camidge DR
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):892-8. PubMed ID: 24462383
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
9. Oligoprogression in Non-Small Cell Lung Cancer.
Harada D; Takigawa N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830977
[TBL] [Abstract][Full Text] [Related]
10. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
[TBL] [Abstract][Full Text] [Related]
11.
Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
[TBL] [Abstract][Full Text] [Related]
12. Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Billing DL; Rimner A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830925
[TBL] [Abstract][Full Text] [Related]
13. Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Suh YG; Cho J
Radiat Oncol J; 2019 Sep; 37(3):149-155. PubMed ID: 31591862
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
Wei H; Zhou X; Yang H; Gong Y; Wang J; Xu Y; Zhou L; Xue J; Zou B; Zhang Y; Zhu J; Peng F; Huang M; Lu Y; Liu Y
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2589-2598. PubMed ID: 34669037
[TBL] [Abstract][Full Text] [Related]
15. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY; Verma V
J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
[TBL] [Abstract][Full Text] [Related]
16. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
17. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Weickhardt AJ; Scheier B; Burke JM; Gan G; Lu X; Bunn PA; Aisner DL; Gaspar LE; Kavanagh BD; Doebele RC; Camidge DR
J Thorac Oncol; 2012 Dec; 7(12):1807-1814. PubMed ID: 23154552
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
19. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC.
Badellino S; Levis M; Cuffini EM; Cerrato M; Orlandi E; Chiovatero I; Aprile A; Gastino A; Cavallin C; Iorio GC; Parise R; Mantovani C; Ricardi U
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326616
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
Ning MS; Gomez DR; Heymach JV; Swisher SG
Transl Lung Cancer Res; 2019 Feb; 8(1):97-106. PubMed ID: 30788239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
